Clinical Trials on Asmd, Visceral Type in Portugal

Total 437 results

Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Multiple Myeloma

France, Poland, Ukraine, Germany, Spain, Israel, Portugal, Slovenia, South Africa, Turkey, Greece, Estonia, Russian Federation, Hungary, Austria, Lithuania, Macedonia, The Former Yugoslav Republic of, Latvia, Croatia, Denmark, A...
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

HIV Infections | HIV-1 | Human Immunodeficiency Virus Type 1

United States, Australia, France, United Kingdom, Taiwan, Spain, Argentina, Portugal, Romania, South Africa, Canada, Denmark, Sweden, Netherlands, Brazil, Puerto Rico, Austria, Russian Federation, Thailand, Mexico
The Lymphoma Academic Research Organisation

Completed

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP (REMARC)

Lymphoma | Diffuse Large B-cell Lymphoma

Belgium, Switzerland, France, Australia, Spain, Israel, Austria, Portugal, Poland
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

Lymphoma, Mantle-Cell

United States, China, Spain, Belgium, Canada, Australia, Czechia, Italy, Taiwan, Germany, Japan, New Zealand, United Kingdom, Denmark, Brazil, Israel, France, Netherlands, Korea, Republic of, Poland, Hungary, Austria, Switzerland, Por... and more
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
Pfizer

Completed

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)

Renal Cell Carcinoma

France, Belgium, Hungary, Taiwan, United States, Australia, Spain, Hong Kong, Malaysia, Serbia, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation and more
Celgene

Completed

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (ORIGIN)

B-Cell Chronic Lymphocytic Leukemia

United States, Spain, Australia, Belgium, Italy, Serbia, Poland, Israel, New Zealand, Portugal, Brazil, France, Bulgaria, Croatia, Czechia, Hungary, Russian Federation, Netherlands, Romania, Denmark, United Kingdom, Austria, Canada, South... and more
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Melanoma

Spain, Italy, Poland, Brazil, Australia, Chile, Canada, Portugal, Turkey, Germany, Greece, Israel, Sweden, New Zealand, United States, Belgium, France, Taiwan, United Kingdom, South Africa, Denmark, Argentina, Colombia, Japan, Switzerland
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
Novartis Pharmaceuticals

Active, not recruiting

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)

Melanoma

Italy, Czechia, Germany, Hungary, Canada, United States, Argentina, Australia, Austria, France, Israel, Russian Federation, Spain, Sweden, United Kingdom, Thailand, Belgium, Brazil, Greece, Switzerland, Mexico, Netherlands, Denmark, C... and more
Hoffmann-La Roche

Completed

A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

Italy, Belgium, Canada, Finland, Ireland, Netherlands, Peru, Spain, United Kingdom, Venezuela, Russian Federation, Brazil, France, Poland, Israel, South Africa, Thailand, Bulgaria, Colombia, Greece, Turkey, Argentina, Saudi Arabia, Uk... and more
BioMarin Pharmaceutical
ICON plc

Completed

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) (MARS)

Mucopolysaccharidosis IV Type A | Morquio A Syndrome | MPS IVA

United States, United Kingdom, Australia, Taiwan, Belgium, Malaysia, Austria, Canada, Portugal, France, Ireland, Czechia, Denmark, Italy, Netherlands, Poland, Puerto Rico
Celgene

Completed

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma (ROBUST)

Lymphoma, Large B-Cell, Diffuse

United States, Australia, Belgium, Canada, China, Czechia, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Switzerland, Taiwan, Turkey
Pfizer

Completed

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Follicular Lymphoma

United States, Spain, United Kingdom, Korea, Republic of, France, Portugal, India, Mexico, Switzerland, Japan, Germany, Romania, Greece, Austria, Belgium, Italy, Thailand, Croatia, Philippines, Russian Federation, Puerto Rico, Ukr... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Malignant Melanoma

Canada, Italy, Czechia, Australia, France, Greece, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Slovakia, Slovenia, Japan, Turkey, Argentina, Finland, Norway, Brazil, Latvia, Lithuania, Poland, Portugal
Pfizer

Completed

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Metastatic or Unresectable Cutaneous Melanoma

United States, Spain, Canada, Italy, United Kingdom, Germany, Korea, Republic of, France, Australia, Czechia, Russian Federation, Turkey, Israel, Netherlands, Greece, Hungary, Japan, Portugal, Argentina, Austria, Belgium, Brazil, Po... and more
Daiichi Sankyo
AstraZeneca

Recruiting

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Gastroesophageal Junction Adenocarcinoma | Gastric Cancer, Adenocarcinoma

Hong Kong, Korea, Republic of, France, United Kingdom, Spain, China, Ireland, Brazil, Japan, Singapore, Belgium, Israel, Russian Federation, Argentina, Chile, Hungary, Poland, Portugal, Taiwan, Turkey, Ukraine, Germany, Romania, Italy
Amgen

Recruiting

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Japan, Australia, Denmark, Netherlands, Taiwan, Switzerland, Canada, France, United States, Austria, Italy, Spain, Sweden, Belgium, Hungary, Finland, Korea, Republic of, Greece, Turkey, Romania, Portugal, Germany, Bulgaria, Mexico, United...
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Celgene

Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)

Multiple Myeloma

United States, Spain, United Kingdom, Italy, Israel, Portugal, Germany, Turkey, Greece, Ireland, Austria, Norway, Netherlands, Denmark, Poland, France, Russian Federation, Canada, Finland, Japan, Puerto Rico, Sweden
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, France, Poland, Belgium, Germany, Spain, Argentina, Colombia, Israel, Portugal, Russian Federation, Turkey, Ukraine, Canada, Greece, Sweden, Korea, Republic of, United Kingdom, Brazil, Mexico, Czechia
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
Takeda

Active, not recruiting

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC)

Myeloid Leukemia, Chronic, Chronic Phase

United States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)

Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, Canada, Taiwan, Germany, Korea, Republic of, Brazil, Japan, Russian Federation, Poland, China, Israel, Belgium, Australia, Austria, Czechia, Portugal, Mexico, Turkey, India, Ukraine
Millennium Pharmaceuticals, Inc.

Completed

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

United States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
Celgene

Withdrawn

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

Esophageal Squamous Cell Carcinoma

United States, France, Spain, Australia, Korea, Republic of, Argentina, Belgium, China, Portugal, Taiwan, Japan, Germany, Poland, Thailand, United Kingdom, Switzerland, Turkey, Russian Federation, Morocco, Greece, Italy, New Zealand, South Africa and more
Hoffmann-La Roche

Terminated

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
BeiGene

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma

United States, Italy, Spain, China, United Kingdom, Australia, Israel, Korea, Republic of, Belgium, France, Brazil, Ireland, Czechia, Romania, Portugal, Georgia, Argentina, Poland, Puerto Rico, Austria, Switzerland
Hoffmann-La Roche

Active, not recruiting

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms, Nerve... and other conditions

Italy, Korea, Republic of, Australia, Spain, Argentina, Belgium, Brazil, France, Portugal, United Kingdom, United States, Japan, Mexico, Poland, Norway, Costa Rica, Switzerland, Netherlands, Germany, Sweden, Turkey, Ireland, Panama
Celgene

Recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

United States, Korea, Republic of, Canada, Chile, Argentina, Australia, Austria, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Japan, Malaysia, Mexico, New Zealand, Norway, Polan... and more
Pfizer

Active, not recruiting

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

Melanoma

Canada, United States, Spain, Germany, Korea, Republic of, Australia, Czechia, Netherlands, France, Hungary, United Kingdom, Switzerland, Singapore, Russian Federation, Italy, Japan, Israel, Brazil, Portugal, Mexico, Greece, Argen... and more
Pfizer

Approved for marketing

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Netherlands, Canada, Bulgaria, Czech Republic, Hungary, Spain, United Kingdom, Greece, Australia, Belgium, France, Germany, Italy, Panama, Russian Federation, Sweden, Brazil, Taiwan, Argentina, Mexico, Serbia, Thailand, Korea, Republic of and more
GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)

Neoplasms, Head and Neck

United States, Argentina, Australia, Spain, Taiwan, Germany, Israel, Poland, Canada, Japan, Portugal, Ireland, Netherlands, China, Brazil, France, Korea, Republic of, Italy, Romania, Russian Federation, United Kingdom, Norway, Switz... and more
Janssen Research & Development, LLC

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

Relapsed or Refractory Multiple Myeloma

United States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Japan, Netherlands, Poland, Austria, Portugal, Greece, India
GlaxoSmithKline

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)

Neoplasms, Head and Neck

United States, Italy, Japan, Norway, Spain, Taiwan, Australia, United Kingdom, Belgium, Brazil, Germany, Greece, Romania, Sweden, Turkey, Canada, Korea, Republic of, China, France, Argentina, India, Poland, Israel, Portugal, Mexico, Czechia, Hunga...
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Pfizer

Terminated

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, China, Taiwan, France, Australia, Hungary, Korea, Republic of, Germany, Japan, Switzerland, Ireland, Israel, United Kingdom, Italy, Poland, Belgium, Canada, Greece, Portugal, Austria, Russian Federation
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Head and Neck Neoplasms

Poland, Canada, Brazil, Belgium, Japan, United States, Argentina, Australia, Austria, Chile, Colombia, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, Portugal, Russian Federation, Spain, Switzerland, Taiwan, Ukraine, United...
Hoffmann-La Roche
Genentech, Inc.

Terminated

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

B-cell Lymphoma

Italy, China, United States, New Zealand, Canada, Australia, Austria, France, Spain, United Kingdom, Brazil, Colombia, Russian Federation, Thailand, Germany, Panama, Peru, Korea, Republic of, Hong Kong, Sweden, Argentina, Ecuador, P... and more
Celgene

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Multiple Myeloma

Austria, Italy, China, Australia, Spain, United States, Korea, Republic of, Taiwan, Germany, Ireland, Argentina, Brazil, Mexico, Netherlands, Belgium, Czechia, France, Greece, Japan, Poland, Israel, United Kingdom, Norway, Denmark, Finland and more
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

B-cell Chronic Lymphocytic Leukemia

United States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
Takeda

Completed

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Multiple Myeloma

France, Spain, United States, Taiwan, Korea, Republic of, Israel, Australia, Czechia, Hungary, Canada, Japan, Portugal, Singapore, United Kingdom, Italy, Sweden, Poland, Germany, China, Denmark, Greece, Thailand, Serbia, Turkey, Colombia, Russian Federation and more
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more

Clinical Trials on Asmd, Visceral Type in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations